A Randomized, Open Label, Multicentre Study to Evaluate the Safety and Efficacy of Cough Mixture CS1 (Pholcodeine and Promethazine - Tixylix) Versus CS2 (Noscapine, Ammonium Chloride, Sodium Citrate) in Treatment of Children with Dry Cough.

The objective of this study was to compare the efficacy and safety of cough mixture containing pholcodeine and promethazine - Tixylix (CS1) to a cough mixture which has noscapine, ammonium chloride, and sodium citrate (CS2) as its constituents in treatment of children suffering from dry cough. A total of 208 patients were enrolled at 4 sites. Of these, 179 (94 receiving CS1 and 99 receiving CS2) completed the study. Results of this study suggest that both the cough mixtures were comparable as per evaluation of their primary parameters. According to global assessment for efficacy and tolerability by parents on Day 7, Group CS1 performed better than CS2. It was also observed that no AE was reported in Group CS1 as compared to 2 AEs in Group CS2. To conclude, cough mixture combination of pholcodeine and promethazine - Tixylix exhibited efficacy and safety that was comparable with cough mixture which has noscapine, ammonium chloride, and sodium citrate. It was proven to be efficacious, safe and well tolerated in the select population.

effect of orally administered gelatin on symptom resolution in chronic persistent cough: a randomized clinical trial study

The term chronic cough signifies the cough lasting for more than three weeks and is associated with different morbidities. Despite its importance, the management is often unsatisfactory. Gelatin is widely used in Iranian traditional medicine for chronic cough. This study aims to test gelatin as a possible therapy for chronic cough. One hundred patients with chronic cough without any other co-morbidities were randomly divided into two groups. The first group continued their previous antitussive medication and the second group received gelatin for 3-5 days. In first group, 52% were female and 48% male [42.9 +/- 12.8 years] while these figures for the 2nd group, were 46% and 54% [41.4 +/- 14.7]. Cough duration in the first group was 6.4 weeks and 6.4 weeks in the second group. In the first group, 16% reported no response to the therapy, 30% poor response, 28% fair response, 18% good response, and 8% excellent response respectively. In the second group, the figures were 4%, 20%, 32%, 38% and 6% respectively. Although the number of participants was not large enough to determine a statistical significance, it seems that gelatin had relieved the patients of their cough more than common antitussive medications. This study can provide the ground for further studies, especially clinical trials to evaluate the efficacy of gelatin for the treatment of chronic persistent cough